This was the final day of the 2024 SGO meeting.
I caught the tail end of the SGO Business meeting which included the passing of the gavel from this years President , Dr Angeles Alvarez-Secord to Dr Amanda Fader.
🔥🔥🔥Passing the gavel and the torch of @SGO_org - thank you @AngelesSecord for your service and best of luck to @amandanfader - you are going to rock #SGOMtg pic.twitter.com/QQzQOyWWHT
— Shannon Westin, MD, MPH, FASCO (@ShannonWestin) March 18, 2024
The next session, Doctor as Patient:Michael Frumovitz, MD,MPH,MS,CPXP was a moving presentation. Dr Frumovitz shared with his medical colleagues what his experience was as physician and stage 3 pancreatic cancer patient. He mentioned how cancer patients run the gamut from those who are private to those who are public about their experiences.
A Predictive Nomogram for Endometrial Cancer based on Pre-operative Assessment in Patients with Endometrial Intraepithelial Neoplasia Dr Ertel #gyncsm #SGOmtg retrospective study of endometrial intraepithelial neoplasia (EIN) model can rule out lymph node dissection . pic.twitter.com/UWCZlRXT7E
— Dee Sparacio (@womenofteal) March 18, 2024
Heated IP chemotherapy (HIPEC) during interval cytoreductive survery was associated with imporved survival.
Heated intraperitoneal chemotherapy is associated w/ improved OS among advanced-stage ovarian cancer patients undergoing interval cytoreductive surgery #SGOmtg #gyncsm Kohut HIPEC was associated with a 14.4-month OS benefit in patients who received neoadjuvant chemo pic.twitter.com/l6G2LJ4FDB
— Dee Sparacio (@womenofteal) March 18, 2024
Criteria to determine need for ileostomy.
Developing Ovarian Cancer Innovative Diversion Criteria (OV-Divert) to decrease the rate of diverting ileostomy in patients undergoing cytoreductive surgery for gynecologic malignancy , DR May #gyncsm #SGOmtg ovarian cancer innovative diversion criteria (Ov-DIVERT) pic.twitter.com/skA180aA5I
— Dee Sparacio (@womenofteal) March 18, 2024
Comparison of 2 drugs used to prevent venous thrombosis.
Setting the standard for postoperative venous thromboembolism prophylaxis in gyn cancer patients: Apixaban showed similar outcomes with lower cost compared to enoxaparin Knisely #gyncsm #SGOMtg Cost $10 Apixiban, $20 enoxaparin pic.twitter.com/wAvAKp3K4s
— Dee Sparacio (@womenofteal) March 18, 2024
Using Text messaging to measure PRO.
Improving Quality of Life using Patient Reported Outcomes Measures Post-operatively via Text messaging: a Randomized Control Trial (PROMPT study) Straubhar , #gyncsm #SGOmtg Symptom tracker to improve QOL based on difference in FACT score
— Dee Sparacio (@womenofteal) March 18, 2024
Trend to improvement in intervention pic.twitter.com/UQ4wY6rVgA
Barriers to fertility preservation
Exploring Preferences & Experiences of Female Cancer Survivors Regarding Fertility and Fertility Preservation: Insights from the Survivorship Oncofertility Barriers Survey Dr Kansberg #gyncsm #SGOmtg Survey of 164 responses
— Dee Sparacio (@womenofteal) March 18, 2024
*Women need to be made aware of fertility options! pic.twitter.com/g2IIKshX8x
Memory Impairment in post menopausal women was associated with increased age and comorbidity not chemotherapy.
Age, comorbidities, and cancer: their associations with memory impairment in postmenopausal gyn cancer survivors #gyncsm #SGOmtg Do women w/ GYN cancers experience higher risk for cognitive impairment compared to cancer-free? Memory prob due to Increase age, comorbitity pic.twitter.com/9GjjEuDg2P
— Dee Sparacio (@womenofteal) March 18, 2024
Another advocate presentation on peer support for Black women with endometrial cancer.
Engaging endometrial cancer survivors as peer supporters for equitable cancer care: The SISTER Study Training Process, A. Moore #gyncsm #SGOmtg
— Dee Sparacio (@womenofteal) March 18, 2024
It is feasible to recruit and train Black EC survivors as peer support facilitators.
So imp! Great Job @AdrienneEcana ! pic.twitter.com/J0iNFQ9KNH
The Fireside Chat: Critical Issues in Gyn Cancers and the Power of Shared Purpose panel included representatives from other gynecologic cancer organizations. They see the need to work together in many areas including improving recruitment of underrepresented peoples to clinical trials. I was pleased to see Annie Ellis, Patient Advocate and Survivor approach the mic at the end and share her thoughts.
Fireside chat time-
— Dee Sparacio (@womenofteal) March 18, 2024
Annie Ellis @Stigetta at the mic telling the panel that Patients want to be PARTNERS! YES!!!
- I agree help us solve problems with you- #gyncsm #SGOmtg pic.twitter.com/2UMDnzyY6v
There was a moving tribute to former SGO President , Dr Wendy Brewster who passed away from pancreatic cancer.
Tribute to Dr Brewster by @sd_yamada
— Dee Sparacio (@womenofteal) March 18, 2024
So moving... Dr Brewster was a FORCE, and worked tirelessly.
I know Dr Brewster was a strong supporter of including patient advocates in the all the work SGO does. #gyncsm #SGOmtg pic.twitter.com/YaqptimFG1
Dr Secord gave her Presidential address. She certainly helped to grow SGO with now over 3000 members.
Thank you Dr @AngelesSecord for your leadership! #gyncsm #SGOmtg pic.twitter.com/6TeQY3MvOv
— Dee Sparacio (@womenofteal) March 18, 2024
Poster session 2 included the abstract that survivor/advocates Annie Ellis, Lynda Ryan, Adrienne Moore and I , submitted. It was so exciting to have our abstract accepted for this poster session.
The final session I attended was Scientific Plenary V Late Breaking Abstract Session 2 .
Endometrial Cancer
Durvalumab + carbo/paclitaxel followed by durvalumab w/ or w/out olaparib 1st line endometrial cancer: in the DUO-E...Trial #gyncsm #SGOmtg
— Dee Sparacio (@womenofteal) March 18, 2024
olaparib enhances chemo and Durvalumab.
pMMR subpopulation further enhanced OS,TFST, PFS2 and TSST compared to Chemo . pic.twitter.com/mWRfNVaOIr
Another Patient presenting her experience in the DUO trial.
#gyncsm #SGOmtg Thank you , Jan Bush , for sharing your experience on the DUO-E trial.
— Dee Sparacio (@womenofteal) March 18, 2024
Thanks again @SGO_org for including patients on panels. pic.twitter.com/GcEyztxR5q
Ovarian Cancer Duo trial using Durvalumab , Bev and Olaparib
Durvalumab + paclitaxel/carb plus bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in advanced ovarian cancer without a tumor BRCA1,.BRCA2 mutation DUO-O... #gyncsm #SGOmtg Harter
— Dee Sparacio (@womenofteal) March 18, 2024
PFS 45.1 mo Arm3 w/ Olaparib vs Arm 1 chemo, pic.twitter.com/1QfPVjxICJ
Chinese study of Niraparib maintenance and Individualized Dosing
Niraparib Maintenancew/ Individualized Starting Dose (ISD) in Platinum-Sensitive Recurrent Ovarian Cancer (NORA): Final OS #gyncsm #SGOmtg favorable OS trend with niraparib using ISD versus placebo pic.twitter.com/5SAqwl0cFp
— Dee Sparacio (@womenofteal) March 18, 2024
The use of a P-53 reactivator in a PH 1 trial.
PYNNACLE Phase 1/2 Study of PC14586 in ( p53 reactivator - Rezatapopt) Patients With Advanced OC Harboring a TP53 Y220C Mutation Dr Schram #gyncsm #SGOmtg 4 prior lines of therapy, 15 patients , ORR 47% , promising efficacy pic.twitter.com/TcQxSPKir3
— Dee Sparacio (@womenofteal) March 18, 2024
Thanks SGO, especially Dr Pothuri, Dr Powell and the entire planning committee for such a well run and informative meeting. Thanks again for going our of your way to including so many survivor-advocates in important meeting presentations, on panels and presenting their posters.
Hope to see you next year in Seattle.
Dee
Every Day is a Blessing!
No comments:
Post a Comment